Table 4.
Overall summary of adverse events
| Exemestane (n = 149) | Anastrozole (n = 149) | |||
|---|---|---|---|---|
| Any cause | Treatment-related | Any cause | Treatment-related | |
| Total AEs, n | 687 | 316 | 796 | 290 |
| Patients who experienced AEs, n (%) | ||||
| Any AE | 136 (91.3) | 106 (71.1) | 131 (87.9) | 89 (59.7) |
| Serious AE | 19 (12.8) | 6 (4.0) | 19 (12.8) | 5 (3.4) |
| Grade 3 or grade 4 AEa | 28 (18.8) | 13 (8.7) | 27 (18.1) | 9 (6.0) |
| Grade 5 AEb | 3 (2.0) | 1 (0.7) | 1 (0.7) | 0 |
| Treatment discontinuation due to AE, n (%) | 10 (6.7) | 5 (3.4) | 9 (6.0) | 3 (2.0) |
AE adverse event
aBased on Common Terminology Criteria for Adverse Events version 3.0 [44]
bDeath related to AEs reported from start of treatment to 7 days after the end of treatment or study withdrawal